Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Pioneering Oxford research to tackle vision loss is set to feature on the BBC’s One Show this week.

The BBC One programme is to feature the story of a patient from Reading who has choroideremia, a progressive loss of vision.

The patient took part in an ongoing gene therapy trial that is being performed at the John Radcliffe Hospital by the Nuffield Laboratory of Ophthalmology, led by University of Oxford Professor and OUH Consultant Ophthalmologist Robert MacLaren.

Choroideremia is a currently incurable genetic eye disorder caused by a mutation in a single gene.The new treatment seeks to replace a ‘normal’ version of that gene, offering the potential to halt or even partially reverse vision loss.

The treatment is delivered to the eye by an injection, underneath the retina, of a virus that contains the correct version of the gene. The injection places the viral particles in the correct anatomical location, and the virus itself delivers the correct copy of the gene into the dysfunctional cells.

A number of patients in this ongoing trial have already been enrolled and received gene therapy. If successful, this technique may be applied more widely to other genetic retinal diseases.

The programme is planned to broadcast on Wednesday, July 8 from 7pm.

Similar stories

NICE recommends offering app-based treatment for people with insomnia instead of sleeping pills

Hundreds of thousands of people suffering from insomnia who would usually be prescribed sleeping pills could be offered an app-based treatment programme instead, NICE has said.

Developmental dynamics of the neural crest–mesenchymal axis in creating the thymic microenvironment

A new paper from researchers at the Department of Paediatrics and the Nuffield Department of Clinical Neurosciences has shown that fibroblasts in the thymus, often considered simply as dull “structural” cells, are much more complex than previously thought.

How to use the science of the body clock to improve our sleep and health

Professor Russell Foster has written a new book about circadian neuroscience which is published by Penguin this week. This book review by Jacqueline Pumphrey was first published on the University of Oxford website.

Funding awarded for autoimmune disease research

Dr Kate Attfield awarded project funding by Connect Immune Research and The Lorna and Yuti Chernajovsky Biomedical Research Foundation.

Oxford researchers part of major UK initiative to understand chronic pain

Oxford pain researchers are playing a major role in a new multi-million pound research programme launched by a consortium of funders, including UKRI, Versus Arthritis, Eli Lilly and the Medical Research Foundation.